Abstract
No translate
No translate
No translate
No translate
Phan Long Nhơn; Hoàng Khánh; Huỳnh Văn Minh
References
1.
1. Zwicker J.I., Furie B.C., và Furie B. (2007). Cancer-associated thrombosis. Crit Rev Oncol Hematol, 62(2), 126–136.
2.
2. TrousseauA.(Armand)(1865), Cliniquemédicaledel’Hôtel-DieudeParis, Paris ; New York : Baillière.
3.
BlomJ.W.,DoggenC.J.M.,OsantoS.vàcộngsự.(2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 293(6), 715–722.
4.
3. TimpJ.F.,BraekkanS.K.,VersteegH.H.vàcộngsự. (2013). Epidemiology of cancer-associated venous thrombosis. Blood, 122(10), 1712–1723.
5.
4. ShenV.S.vàPollakE.W.(1980). Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J, 73(7), 841–843.
6.
5. KhoranaA.A.,FrancisC.W.,CulakovaE.vàcộngsự.(2007). Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. JThrombHaemost, 5(3), 632–634.
7.
6. HeitJ.A.,MohrD.N.,SilversteinM.D.vàcộngsự.(2000). Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. ArchInternMed, 160(6), 761–768.
8.
7. Ruf,W.;Edgington,T.S. Structural biology of tissue factor, the initiator of thrombogenesis in vivo.FASEB J.1994, 8, 385–390.
9.
8. Khorana,A.A.;Ahrendt,S.A.;Ryan,C.K.;Francis,C.W.;Hruban,R.H.;Hu,Y.C.;Hostetter,G.;Harvey, J.; Taubman, M.B. Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer.Clin. Cancer Res. 2007, 13, 2870–2875.
10.
9. Uno,K.;Homma,S.;Satoh,T.;Nakanishi,K.;Abe,D.;Matsumoto,K.;Oki,A.;Tsunoda,H.; Yamaguchi, I.;Nagasawa, T.; et al. Tissue factor expression as a possible determinant of thromboembolism in ovariancancer. Br. J. Cancer 2007, 96, 290–295.
11.
10. Dvorak,H.;Quay,S.;Orenstein,N.;Dvorak,A.;Hahn,P.;Bitzer,A.;Carvalho,A. Tumor shedding and coagulation. Science 1981, 212, 923–924.
12.
11. Suzuki-Inoue, K.; Kato, Y.; Inoue, O.; Kaneko, M.K.; Mishima, K.; Yatomi, Y.; Yamazaki, Y.; Narimatsu,H.;Ozaki,Y. Involvement of the Snake Toxin Receptor CLEC-2, in Podoplanin-mediated Platelet Activation, by Cancer Cells. J. Biol. Chem. 2007, 282, 25993–26001.
13.
12. Lupu-Meiri, M.; Geras-Raaka, E.; Lupu, R.; Shapira, H.; Sandbank, J.; Segal, L.; Gershengorn, M.C.;Oron, Y.Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells. J. Cell. Physiol. 2012, 227, 3621–3628.
14.
13. Westrick,R.;Eitzman,D. Plasminogen activator inhibitor-1 in vascular thrombosis. Curr. Drug Targets 2007,8, 966–1002.
15.
14. Gordon,S.S. A proteolytic procoagulant associated with malignant transformation. J. Histochem. Cytochem. 1981, 29, 457–463.
16.
15. Grignani,G.;Jamieson,G.A. Platelets in tumor metastasis: Generation of adenosine diphosphate by tumor cells is specific but unrelated to metastatic potential. Blood1988, 71, 844.
17.
16. Falanga, A.; Panova-Noeva, M.; Russo, L. Procoagulant mechanisms in tumour cells. Best Pract. Res. Clin. Haematol. 2009, 22, 49–60.
18.
17. Kanno,K.;Hirata,Y.;Imai,T.;Iwashina,M.;Marumo,F. Regulation of inducible nitric oxide synthase gene by interleukin-1 beta in rat vascular endothelial cells. Am.J.Physiol.Heart Circ. Physiol. 1994, 267, H2318–H2324.
19.
18. Johnson, A.; Phelps, D.T.; Ferro, T.J. Tumor necrosis factor-alpha decreases pulmonary artery endothelial nitrovasodilator via protein kinase C. Am. J. Physiol. Lung Cell. Mol. Physiol. 1994, 267, L318–L325.
20.
19. Clauss,M. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J.Exp.Med.1990, 172, 1535–1545.
21.
20. Caplan,M.S.;Adler,L.;Kelly,A.;Hsueh,W.Hypoxia increases stimulus-induced PAF production and release from human umbilical vein endothelial cells. Biochim. Biophys. Acta 1992, 1128, 205–210.
22.
21. Hernandez,C.;Huebener,P.;Schwabe,R.F. Damage-associated molecular patterns in cancer: A double-edged sword. Oncogene 2016, 35, 5931–5941.
23.
22. Lechner,D.;Kollars,M.;Gleiss,A.;Kyrle,P.A.;Weltermann,A. Chemotherapy - induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J. Thromb.Haemost. 2007, 5, 2445–2452.
24.
23. Lindahl,A.K.;Odegaard,O.R.;Sandset,P.M.;Harbitz,T.B. Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. Cancer1992, 70, 2067–2072.
25.
24. Silverstein M.D., Heit J.A., Mohr D.N. và cộng sự. (1998). Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med, 158(6), 585–593.
26.
25. KhoranaA.A.,FrancisC.W.,CulakovaE.vàcộngsự.(2007). Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer, 110(10), 2339–2346.
27.
26. VergatiM.,Della-MorteD.,FerroniP.vàcộngsự.(2013). Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer. RejuvenationRes, 16(3), 224–231.
28.
27. Incidence of venous thromboembolism and its effect on survival among patients with common cancers.PubMed - NCBI.ps://www.ncbi.nlm.nih.gov/pubmed/16505267>, accessed: 04/07/2019.
29.
28. Incidence of venous thromboembolism in patients hospitalized with cancer. - PubMed - NCBI.ps://www.ncbi.nlm.nih.gov/pubmed/16431186>, accessed: 04/07/2019.
30.
29. Epidemiology and Risk Factors for Venous Thrombosis. ps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2020806/>, accessed: 04/07/2019.
31.
30. AgnelliG.,BolisG.,CapussottiL.vàcộngsự.(2006). A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. AnnSurg, 243(1), 89–95.
32.
31. Levi M. (2014). Cancer-related coagulopathies. Thrombosis Research, 133, S70–S75.
33.
32. Cronin-FentonD.P.,SøndergaardF.,PedersenL.A.vàcộngsự.(2010). Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer, 103(7), 947–953.
34.
33. BlomJ.W.,DoggenC.J.M.,OsantoS.vàcộngsự.(2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 293(6), 715–722.
35.
34. AhlbrechtJ.,DickmannB.,AyC.vàcộngsự.(2012). Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. JClinOncol, 30(31), 3870–3875.
36.
35. Naess I.A., Christiansen S.C., Romundstad P. và cộng sự. (2007). Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost, 5(4), 692–699.
37.
36. ClarkS.R.,MaA.C.,TavenerS.A.vàcộngsự.(2007). Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. NatMed, 13(4), 463–469.
38.
37. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. - PubMed - NCBI. ps://www.ncbi.nlm.nih.gov/pubmed/15456487>,accessed: 04/07/2019.
39.
38. KhoranaA.A.vàConnollyG.C.(2009). Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol, 27(29), 4839–4847.
40.
39. EichingerS.(2016). Cancer associated thrombosis: risk factors and outcomes. ThrombRes, 140 Suppl 1, S12-17.
41.
40. Coagulation in Cancer | David Green | Springer. ps://www.springer.com/gp/book/ 9780387799612>, accessed: 04/07/2019.
42.
41. PiovellaF.,WangC.-J.,LuH.vàcộngsự.(2005). Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost, 3(12), 2664–2670.
43.
42. KhoranaA.A.,DalalM.,LinJ.vàcộngsự.(2013). Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer, 119(3), 648–655.
44.
43. DollD.C.(1986). Acute Vascular Ischemic Events After Cisplatin-Based Combination Chemotherapy for Germ-Cell Tumors of the Testis. Ann Intern Med, 105(1), 48.
45.
44. CzaykowskiP.M.,MooreM.J.,vàTannockI.F.(1998). High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. JUrol, 160(6 Pt 1), 2021–2024.
46.
45. NalluriS.R.,ChuD.,KeresztesR.vàcộngsự.(2008). Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA, 300(19), 2277–2285.
47.
46. Lee A.Y.Y., Levine M.N., Butler G. và cộng sự. (2006). Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol, 24(9), 1404–1408.
48.
47. Biomarkers for prediction of venous thromboembolism in cancer. - PubMed - NCBI. ps://www. ncbi.nlm.nih.gov/pubmed/23908470>, accessed: 04/07/2019.
49.
48. Ay C., Vormittag R., Dunkler D. và cộng sự. (2009). D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol, 27(25), 4124–4129.
50.
49. LipG.Y.H.,ChinB.S.P.,vàBlannA.D.(2002). Cancer and the prothrombotic state. LancetOncol, 3(1), 27–34.
51.
50. VormittagR.,SimanekR.,AyC.vàcộngsự.(2009). High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. ArteriosclerThrombVascBiol, 29(12), 2176–2181.
52.
51. GeddingsJ.E.vàMackmanN.(2013). Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood, 122(11), 1873–1880.
53.
52. ThalerJ.,PreusserM.,AyC.vàcộngsự.(2013). Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. ThrombRes, 131(2), 162–165.
54.
53. WangJ.-G.,GeddingsJ.E.,AlemanM.M.vàcộngsự.(2012). Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood, 119(23), 5543–5552.
55.
54. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis- PubMed - NCBI.
56.
55. KhoranaA.A.,KudererN.M.,CulakovaE.vàcộngsự.(2008). Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 111(10), 4902–4907.
57.
56. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. - PubMed - NCBI. www.ncbi.nlm.nih.gov/pubmed/22652600>, accessed: 04/07/2019.
58.
57. Neutrophil extracellular traps promote deep vein thrombosis in mice. - PubMed - NCBI. www.ncbi.nlm.nih.gov/pubmed/22044575>, accessed: 04/07/2019.
59.
58. GouldT.J.,VuT.T.,SwystunL.L.vàcộngsự.(2014). Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. ArteriosclerThrombVascBiol, 34(9), 1977–1984.
60.
59. SchwarzenbachH.,HoonD.S.B.,vàPantelK.(2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer, 11(6), 426–437.
61.
60. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. - PubMed - NCBI. ps://www.ncbi.nlm.nih.gov/pubmed/29353682>, accessed: 03/07/2019.
62.
61. KhoranaA.A.(2009). Cancer and thrombosis: implications of published guidelines for clinical practice.AnnOncol, 20(10), 1619–1630.
63.
62. LouzadaM.L.,CarrierM.,Lazo-LangnerA.vàcộngsự.(2012). Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation, 126(4), 448–454.
64.
63. Louzada M.L., Carrier M., Lazo-Langner A. và cộng sự. Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism. 7.
Tác giả
Vũ Thị Mai: Đại học Y Hà Nội;
Văn Đức Hạnh: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Trần Ngọc Cầm: Bác sĩ nội trú, Đại học Y Hà Nội;
Bùi Anh Thông: Đại học Y Hà Nội;
Phan Đình Phong: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Phạm Mạnh Hùng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Files
Article Views909
Document Views1
Downloads6
Section
CHUYÊN ĐỀ
Issue
Số 90, 2019
Category
BỆNH LÝ MẠCH MÁU NGOẠI BIÊN
Pages
27-39
Copyright Holder
2019 Tạp chí Tim mạch học Việt Nam